Indeed, a study conducted by Wang et al. shows that resistin is able to drive to BC progression by inducing stem and mesenchymal features in malignant cells through the Toll like receptor 4/nuclear factor kappa-light-chain-enhancer of activated B cells/STAT3 (TLR4/ NF-κB /STAT3) axis [40]. The gene discussed is RETN; the disease is breast cancer.